Autolus’ Aucatzyl is a B-lymphocyte antigen CD19 CAR-T cell therapy. Credit: NDAB Creativity via Shutterstock. Autolus ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

After being asked about AI use cases at the September Goldman Sachs conference, AWS CEO Garman talked about pharmaceutical ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

The Nigeria Customs Service (NCS) has announced the seizure of 16 containers of illicit substances and unregistered pharmaceutical products ...

Kroger will pay Oregon up to $40 million as part of a $1.37 billion settlement with 30 states for its alleged role in the ...

William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today. Sami Corwin’s rating is ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

Q3 2024 Earnings Call Transcript November 6, 2024 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.918 ...

In part two of our showcase of six AI manufacturing lighthouses, hear what experts at AstraZeneca, Mengniu Dairy and Midea Group told the WEF ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading.